Revvity Reports Mixed Q3 Revenue, Raises 2025 Profit Outlook, Announces $1B Buyback

Revvity, a health-science solutions company, reported a third-quarter profit decline to $46.7 million, or 40 cents per share, down from $94.4 million a year earlier, despite a 2.2% revenue increase to $699 million. Adjusted earnings per share beat expectations at $1.18 versus the anticipated $1.14, reflecting stronger operational performance amid rising costs and market challenges. The company's Life Sciences and Diagnostics segments showed modest revenue growth of 1% and 3%, respectively, though both experienced lower profit margins compared to the previous year. Revvity raised its full-year adjusted earnings guidance to a range of $4.90 to $5.00 per share, with revenue expected between $2.83 billion and $2.88 billion, maintaining an organic growth forecast of 2% to 4%. Additionally, the board authorized a new $1 billion share repurchase program replacing the prior one, signaling confidence in the company's long-term strategy. Market reaction was mixed, with shares falling slightly despite the earnings beat due to a slight revenue miss and ongoing challenges including tariff impacts and manufacturing adjustments.